Add to ORKGProstate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysi
International audiencePURPOSE: To assess the relationship between prognostic factors, postradiation ...
High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cance
Objective: Serum prostate specific antigen (PSA) is commonly used to evaluate treatment response aft...
PURPOSE: Controversy exists whether the prostate-specific antigen (PSA) bounce phenomenon following ...
Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prosta...
PurposeTo investigate the association between prostate specific antigen (PSA) bounce and disease out...
<p>Brachytherapy is a high-tech, mini-invasive, and effective treatment modality for prostate cancer...
BACKGROUND. The posttreatment prostate-specific antigen (PSA) bounce phenomenon has been recognized...
Prostate-specific antigen (PSA) bounce is common in patients undergoing 125I brachytherapy (BT), and...
Background: PSA kinetics after curative radiotherapy for prostate cancer is an important part of the...
SummaryBackgroundThe serum prostate-specific antigen (PSA) test is the most commonly used method for...
Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fra...
Objective: To determine the usefulness of prostate-specific antigen (PSA) percentage (vs. pretreatme...
Background: Interstitial brachytherapy for localised prostate cancer may be followed by transient in...
Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for pr...
International audiencePURPOSE: To assess the relationship between prognostic factors, postradiation ...
High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cance
Objective: Serum prostate specific antigen (PSA) is commonly used to evaluate treatment response aft...
PURPOSE: Controversy exists whether the prostate-specific antigen (PSA) bounce phenomenon following ...
Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prosta...
PurposeTo investigate the association between prostate specific antigen (PSA) bounce and disease out...
<p>Brachytherapy is a high-tech, mini-invasive, and effective treatment modality for prostate cancer...
BACKGROUND. The posttreatment prostate-specific antigen (PSA) bounce phenomenon has been recognized...
Prostate-specific antigen (PSA) bounce is common in patients undergoing 125I brachytherapy (BT), and...
Background: PSA kinetics after curative radiotherapy for prostate cancer is an important part of the...
SummaryBackgroundThe serum prostate-specific antigen (PSA) test is the most commonly used method for...
Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fra...
Objective: To determine the usefulness of prostate-specific antigen (PSA) percentage (vs. pretreatme...
Background: Interstitial brachytherapy for localised prostate cancer may be followed by transient in...
Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for pr...
International audiencePURPOSE: To assess the relationship between prognostic factors, postradiation ...
High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cance
Objective: Serum prostate specific antigen (PSA) is commonly used to evaluate treatment response aft...